Drug price reform in the UK: debunking the myths.

Drug price reform in the UK: debunking the myths. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Drug price reform in the UK: debunking the myths. Abstract Text:

Simeon Thornton,

The OFT report into the Pharmaceutical Price Regulation Scheme (PPRS) called for reform of the scheme, replacing existing profit and price controls with a system of value-based pricing (VBP). The report argued that VBP would be much more effective than the current PPRS both at providing value for money for the NHS and giving pharmaceutical companies the right incentives to invest in drugs in the future.The report has sparked a widespread debate about drug pricing in the UK and has been controversial in some quarters. Some of the more negative responses are, however, based on fundamental misconceptions about the OFT recommendations. In particular, contrary to some claims, the recommended system would provide strong incentives for incremental innovation and the right balance of rewards for first in class and follow-on products. Nor, as is sometimes argued, would VBP have an adverse effect on investment in the UK.Certainly, real challenges lie ahead if VBP is to be implemented. These concern the definition of value, particularly where patient benefits differ significantly by subgroup or indication, and the level of resource required to implement VBP. The OFT report contains proposals for addressing each of these areas. Perhaps the most difficult challenge is the political one: securing acceptance for a reform package that would create winners and losers among pharmaceutical companies according to their success in producing valuable drugs. Ultimately, however, only a scheme that does precisely this can hope to meet the needs of patients, the NHS and innovative companies in the long run.

Drug price reform in the UK: debunking the myths. Publishing Authors By Initials

S Thornton,

For similar health care economics and organizations: state medicine research abstracts see: health care economics and organizations: state medicine research

PUBMED ID PMID:

MEDLINE DATE:

Drug price reform in the UK: debunking the myths. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Health economics

VOLUME: 16

Page Numbers: 981-92

Journal Abbreviation:

ISSN: 1057-9230

DAY: 20

MONTH: Oct

YEAR: 2007

Drug price reform in the UK: debunking the myths. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9306780

Drug price reform in the UK: debunking the myths. Keywords Mesh Terms:

KEYWORDS: State Medicine

MESH TERMS: organization & administration

Chemical & Substance for Abstract: Drug price reform in the UK: debunking the myths. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Drug price reform in the UK: debunking the myths.

AFFILIATION: SimeonThornton@yahoo.co.uk

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Health Econ

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Drug price reform in the UK: debunking the myths Related Publications

• An evolvable oestrogen receptor activity sensor: development of a modular system for integrating multiple genes into the yeast genome.
• Calcium-dependent protein interactions in MUC5B provide reversible cross-links in salivary mucus.
• Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1.
• Cognate ligand domain mapping for enzymes.
• Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1).
• Coupled composition-deformation phase-field method for multicomponent lipid membranes.
• DAYCENT national-scale simulations of nitrous oxide emissions from cropped soils in the United States.
• Death certificates.
• Does gel affect cytology or comfort in the screening papanicolaou smear?
• Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial.
• Effects of branch length uncertainty on Bayesian posterior probabilities for phylogenetic hypotheses.
• Exploring mental-state reasoning as a social-cognitive mechanism for social loafing in children.
• Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B.
• Induction of bone morphogenetic protein-2 by interleukin-1 in human fibroblasts.
• Is there a star tree paradox?
• Linear stability analysis for step meandering instabilities with elastic interactions and Ehrlich-Schwoebel barriers.
• Looking with both eyes open: fact and value in psychiatric diagnosis?
• Malice/gross negligence.
• Mechanistic approaches to the study of evolution: the functional synthesis.
• Muc5b and Muc5ac are the major oligomeric mucins in equine airway mucus.
• Muscle growth after postdevelopmental myostatin gene knockout.
• Need for cognition and psychosocial adjustment in prostate cancer patients and partners.
• Pathological evidence in malpractice trials.
• Performance of the VUV beamline 4.1 at the SRS, Daresbury Laboratory.
• Physical characterization of a low-charge glycoform of the MUC5B mucin comprising the gel-phase of an asthmatic respiratory mucous plug.
• RNA-dominant diseases.
• Recovery of medical expenses in Texas.
• Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy.
• The influence of parents' marital quality on adult children's attitudes toward marriage and its alternatives: main and moderating effects.
• Towards fully automated structure-based function prediction in structural genomics: a case study.